Is Calcium polystyrene sulfonate registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 5 valid registrations of Calcium polystyrene sulfonate, including RESINCALCIO POWDER FOR SUSPENSION (99.75 %, Powder for oral/rectal suspension, SAR 156.50); RESOCAL 99.934% POWDER FOR USE IN DRINKING WATER (99.934 %, Powder for oral/rectal suspension, SAR 197.35); ROMACIN POWDER FOR ORAL/RECTAL Suspension (99.934 %, Powder for oral/rectal suspension, SAR 177.60); Resincalcio (99.75 %, Powder for oral suspension, SAR 106.00).

Active substance

Calcium polystyrene sulfonate

SFDA 6
Health Canada 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
RESINCALCIO POWDER FOR SUSPENSION	99.75 %	Powder for oral/rectal suspension · Oral use	1 Bottle	SAR 156.50	Generic · Prescription	Laboratorios Rubió; S.A.	Valid
RESOCAL 99.934% POWDER FOR USE IN DRINKING WATER	99.934 %	Powder for oral/rectal suspension · Oral use	1 Jar	SAR 197.35	Generic · Prescription	DEEF PHARMACEUTICAL INDUSTRIES	Valid
RESOCAL 99.934% POWDER FOR USE IN DRINKING WATER	99.934 %	Powder for oral/rectal suspension · Oral use	20 Sachet	SAR 197.35	Generic · Prescription	DEEF PHARMACEUTICAL INDUSTRIES	Valid
ROMACIN POWDER FOR ORAL/RECTAL Suspension	99.934 %	Powder for oral/rectal suspension · Oral, Rectal	1 Jar	SAR 177.60	Generic · Prescription	Alrai Pharmaceutical industry Co. (L.L.C)	Valid
Resincalcio	99.75 %	Powder for oral suspension · Oral use	26 Sachet	SAR 106.00	Generic · Prescription	Laboratorios Rubió; S.A.	Valid
CALCIUM RESONIUM POWDER	99.934 %	Powder for oral/rectal suspension · Oral use	1 Multidose container	SAR 242.90	NCE · Prescription	SANOFI-SYNTHLABO	Withdrawn by MAH · Not Marketed

Indications — CHI Daman Drug Formulary

CHRONIC KIDNEY DISEASE-HYPERKALEMIA; HYPERKALEMIA

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
RESONIUM CALCIUM	02017741	999 MG / G	POWDER FOR SOLUTION · ORAL; RECTAL	SANOFI-AVENTIS CANADA INC

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.